Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

Tremelimumab plus durvalumab (the STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC); however, it demonstrates limited efficacy, with an objective response rate (ORR) of only 20.1%. Radiation therapy (RT) is highly effective in controlling localized solid tumors and has become an integral component of the treatment algorithm for unresectable HCC. Preclinical studies have shown that combining RT with PD-L1/PD-1 blockade promotes immunogenic cell death and enhances antigen presentation by dendritic cells, thereby boosting systemic T cell-mediated an

Trial Details

NCT ID
NCT06999707
Phase
PHASE2
Sponsor
Chang Gung Memorial Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Photon radiotherapy
  • Tremelimumab
  • Durvalumab
Locations (sample)
  • Taoyuan City, Taiwan, Taiwan|24.99368,121.29696

Key Eligibility Criteria

  • Participants must have diagnosis of HCC that is deemed unsuitable for surgical resection or transplant. Participants may have multiple lesions with…
  • Histologically or cytologically proven diagnosis of HCC.
  • Typical arterial enhancement and delayed washout on multiphasic CT or MRI.
  • Age ≥18 years at the time of signing informed consent document.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →